Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review-Reference-Cited by-同舟云学术

Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review

Published:2022-08 Issue: Volume:Volume 16 Page:2885-2894
ISSN:1177-5483
Container-title:Clinical Ophthalmology
language:en
Short-container-title:OPTH

Author:

Giunta Michel,Gauvin Meunier Louis-Pierre,Nixon Donald,Steeves Jeff,Noble Jason

Publisher

Informa UK Limited

Subject

Ophthalmology

Reference39 articles.

1. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis

2. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

3. National Eye Institute. Age-related macular degeneration (AMD) data and statistics. Available from: https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/age-related-macular-degeneration-amd-data-and-statistics. Accessed May 3, 2022.

4. Prevalence of Age-Related Macular Degeneration in the US Population

5. Fifteen-Year Cumulative Incidence of Age-Related Macular Degeneration

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-acting delivery and therapies for neovascular age-related macular degeneration;Expert Opinion on Biological Therapy;2024-07-22

2. The neuroprotective effect of human primary astrocytes in multiple sclerosis: In vitro model;PLOS ONE;2024-04-02

3. Brolucizumab in recalcitrant neovascular age-related macular degeneration–real-world data in Chinese population;PLOS ONE;2024-04-02

4. Incidence and Risk factors of Intraocular Inflammation after Brolucizumab Treatment in Japan: A Multicenter AMD Study;Retina;2023-11-28

5. Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis;Clinical Ophthalmology;2023-09